Helmy M. Siragy


Primary Appointment

Professor, Medicine- Endocrinology and Metabolism


  • Fellowship, Endocrinology & Hypertension, The University of Texas Health Science Center at San Antonio
  • Fellowship, Endocrinology & Hypertension, University of Virginia
  • MD, Tanta University
  • Residency, Internal Medicine, University of Texas, Galveston

Research Disciplines

Cardiovascular Biology, Physiology, Translational Science

Research Interests

Endocrine hypertension, angiotensin receptors, renal paracrine hormones

Research Description

An international expert on subjects related to hypertension, Dr. Siragy was the first to discover that stimulation of angiotensin AT2 receptor leads to generation of nitric oxide. Siragy has authored more than 250 medical journal articles and abstracts, and numerous medical textbook chapters, including a chapter on the kidney and the renin angiotensin system in the Braunwald Atlas of Heart Diseases; a chapter on angiotensin and diabetic nephropathy in Harrison's on-line textbook of Medicine; and a chapter on the angiotensin receptor in Hypertension: A Companion to Brenner. Dr Siragy's primary research interests are in the areas of the renin-angiotensin system, cardiac ischemia, diabetic nephropathy and (Pro)Renin receptor.

Personal Statement

Dr. Siragy is a fellow of the American College of Physicians and the American Heart Association, and a member of numerous national and international endocrine and hypertension societies. He serves as a grant reviewer for the National Institutes of Health and the American Heart Association, among other organizations, and is on the editorial boards of journals in the areas of hypertension, endocrinology, and vascular biology. He edits the section on â??Antihypertensive Agents: Mechanisms of Drug Actions for the journals Current Hypertension Reports and Current Hypertension Reviews.

Selected Publications

Quadri S, Siragy HM, Regulation of (pro)renin receptor expression in mIMCD via the GSK-3β-NFAT5-SIRT-1 signaling pathway., 2014; American journal of physiology. Renal physiology. 307(5) F593-600. PMID: 24990896

Huang J, Ledford KJ, Pitkin WB, Russo L, Najjar SM, Siragy HM, Targeted deletion of murine CEACAM 1 activates PI3K-Akt signaling and contributes to the expression of (Pro)renin receptor via CREB family and NF-κB transcription factors., 2013; Hypertension. 62(2) 317-23. PMID: 23734002 | PMCID: PMC3793251

Matavelli LC, Huang J, Siragy HM, In vivo regulation of renal expression of (pro)renin receptor by a low-sodium diet., 2012; American journal of physiology. Renal physiology. 303(12) F1652-7. PMID: 23077099 | PMCID: PMC3532474

Waeber B, Siragy HM, Mild hypertension: to treat or not to treat?, 2012; Current hypertension reports. 15(1) 1-2. PMID: 23152161

Matavelli LC, Siragy HM, Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats., 2012; Journal of cardiovascular pharmacology. 61(1) 17-22. PMID: 23011470 | PMCID: PMC3538933

Huang J, Siragy HM, Sodium depletion enhances renal expression of (pro)renin receptor via cyclic GMP-protein kinase G signaling pathway., 2011; Hypertension. 59(2) 317-23. PMID: 22203739 | PMCID: PMC3266459

Siragy HM, To ACCELERATE hypertension control., 2011; Current hypertension reports. 13(4) 259-61. PMID: 21494776

Matavelli LC, Huang J, Siragy HM, Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats., 2011; Journal of cardiovascular pharmacology. 59(3) 281-7. PMID: 22075749 | PMCID: PMC3296909

Siragy HM, A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors., 2011; Vascular health and risk management. 7() 297-313. PMID: 21633727 | PMCID: PMC3104607

Abadir PM, Walston JD, Carey RM, Siragy HM, Angiotensin II Type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNFα production., 2011; Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 31(6) 471-4. PMID: 21288138 | PMCID: PMC3104285

Huang J, Matavelli LC, Siragy HM, Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade., 2011; Clinical and experimental pharmacology & physiology. 38(4) 215-21. PMID: 21265872 | PMCID: PMC3077929

Siragy HM, Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations., 2011; Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 25(1) 87-97. PMID: 21213120